Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA-2 CAR-T in Relapsed/Refractory B-cell Lymphoma
NCT06323525Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- CRISPR-Cas9, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ATHENA-2 CAR-T in B-cell non-Hodgkin lymphoma, sponsored by Chinese PLA General Hospital. Started Apr 2024; status: recruiting.
02
Drugs
ATHENA-2 CAR-T
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06323525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06323525.